ANALISIS D-DIMER DAN CRP PADA PASIEN COVID-19 DENGAN KOMORBID DIABETES MELLITUS
DOI:
https://doi.org/10.33992/meditory.v11i1.2484Abstract
Background: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) is a virus that attacks and causes respiratory problems. Patients with comorbid diabetes mellitus are in the high-risk category if they get infected with COVID-19, with a 50% risk of death compared to those without diabetes mellitus. In Covid-19 patients, coagulation disorders are often found, and D-Dimer examination and CRP levels for inflammatory processes must bechecked to assess the continuity of the coagulation process. Aims: This research aims to analyze D-dimer and CRP levels in confirmed Covid-19 patients with comorbid diabetes mellitus at the Jakarta Haji Hospital. Methods: The research is a cross-sectional research design. Data was taken from medical records of patients aged over 25 years who were treated with confirmed Covid-19 with comorbid diabetes mellitus at the Jakarta Haji Hospital for the period June 2021-September 2021 and obtained data for 80 people. Results:Patient characteristics for this research in the majority age group came from adults (25-55 years), as many as 45 people (56%), the sex group of the majority of male patients totalling 44 people (55%), and Blood Glucose Levels during with the largest group in the group that has levels of 200 –300 mg/dl of 57 people (71%). Analysis of D-Dimer levels showed that 50 people (63%) had high values (> 5 ng/mL), while CRP levels showed that 55 people (69%) had high values (> 60 mg/dL). Conclusion: COVID-19 patients with comorbid Diabetes Mellitus have increased levels of D-Dimer and CRP with mean results are 7.0 ng/mL and 68.5 mg/dL.
References
WHO. COVID-19 diagnostic testing in the context of international travel: scientific brief, 16 December 2020. World Health Organization; 2020.
Rhodes R. Justice and guidance for the COVID-19 pandemic. Am J Bioeth. 2020;20(7):163–6.
Humairo A, Pratiwi AY, Mariyam S, Hasanah N. Upaya Pencegahan Pemutusan Mata Rantai Penularan Virus Corona Di Yayasan Pondok Pesantren Al-Hanif Kota Tangerang Selatan. J Pengabdi Kpd Masy Kreasi Mhs Manaj. 2021;1(1):28–32.
Yao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. J intensive care. 2020;8:1–11.
Yu B, Li X, Chen J, Ouyang M, Zhang H, Zhao X, et al. Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis. J Thromb Thrombolysis. 2020;50:548–57.
Moreno G, Carbonell R, Bodà M, RodrÃguez A. Systematic review of the prognostic utility of D-dimer, disseminated intravascular coagulation, and anticoagulant therapy in COVID-19 critically ill patients. Med Intensiva (English Ed. 2021;45(1):42–55.
Long H, Nie L, Xiang X, Li H, Zhang X, Fu X, et al. D-dimer and prothrombin time are the significant indicators of severe COVID-19 and poor prognosis. Biomed Res Int. 2020;2020.
Herold T, Jurinovic V, Arnreich C, Lipworth BJ, Hellmuth JC, von Bergwelt-Baildon M, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol. 2020;146(1):128–36.
Ryoo SM, Han KS, Ahn S, Shin TG, Hwang SY, Chung SP, et al. The usefulness of C-reactive protein and procalcitonin to predict prognosis in septic shock patients: A multicenter prospective registry-based observational study. Sci Rep. 2019;9(1):1–8.
Ali N. Elevated level of Câ€reactive protein may be an early marker to predict risk for severity of COVIDâ€19. J Med Virol. 2020;92(11):2409.
Bajgain KT, Badal S, Bajgain BB, Santana MJ. Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature. Am J Infect Control. 2021;49(2):238–46.
Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med. 2020;2:1069–76.
Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr Clin Res Rev. 2020;14(4):303–10.
Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, et al. COVID-19 and comorbidities: Deleterious impact on infected patients. J Infect Public Health. 2020;13(12):1833–9.
Aufar AF, Raharjo ST. Kegiatan relaksasi sebagai coping stress di masa pandemi COVID-19. J Kolaborasi Resolusi Konflik. 2020;2(2):157–63.
Wati L, Nugraheni DM, Ratnaningrum K, Novitasari A. C-REACTIVE PROTEIN BERKORELASI TERHADAP KADAR D-DIMER PASIEN COVID-19. Al-Iqra Med J J Berk Ilm Kedokt. 2022;5(1):1–9.
Nanda CCS, Indaryati S, Koerniawan D. DM Pengaruh Komorbid Hipertensi dan Diabetes Mellitus terhadap Kejadian COVID-19: Comorbid COVID-19. J Keperawatan Florence Nightingale. 2021;4(2):68–72.
Abdi A, Jalilian M, Sarbarzeh PA, Vlaisavljevic Z. Diabetes and COVID-19: A systematic review on the current evidences. Diabetes Res Clin Pract. 2020;166:108347.
Fauzia NS. Faktor Risiko Terjadinya Coronavirus Disease 2019 Pada Pasien Dengan Komorbid Diabetes Melitus. Arter J Ilmu Kesehat. 2021;2(4):105–12.
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–4.
Iba T, Levy JH, Levi M, Thachil J. Coagulopathy in COVIDâ€19. J Thromb Haemost. 2020;18(9):2103–9.
Potempa LA, Rajab IM, Hart PC, Bordon J, Fernandez-Botran R. Insights into the use of C-reactive protein as a diagnostic index of disease severity in COVID-19 infections. Am J Trop Med Hyg. 2020;103(2):561.
Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect. 2020;50(4):332–4.
Pepys MB. C-reactive protein predicts outcome in COVID-19: is it also a therapeutic target? Eur Heart J. 2021;42(23):2280.
Sharifpour M, Rangaraju S, Liu M, Alabyad D, Nahab FB, Creel-Bulos CM, et al. C-Reactive protein as a prognostic indicator in hospitalized patients with COVID-19. PLoS One. 2020;15(11):e0242400.
Downloads
Published
Issue
Section
Citation Check
License
- Articles published in Meditory are licensed under a Creative Commons Attribution-ShareAlike 4.0 International license. You are free to copy, transform, or redistribute articles for any lawful purpose in any medium, provided you give appropriate credit to the original author(s) and Meditory, link to the license, indicate if changes were made, and redistribute any derivative work under the same license.
- Copyright on articles is retained by the respective author(s), without restrictions. A non-exclusive license is granted to Meditory to publish the article and identify itself as its original publisher, along with the commercial right to include the article in a hardcopy issue for sale to libraries and individuals.
- By publishing in Meditory, authors grant any third party the right to use their article to the extent provided by the Creative Commons Attribution-ShareAlike 4.0 International license.
